^
    Back
    Association details:
    Biomarker:TMEM225B rs10273424
    Cancer:Breast Cancer
    Drug:docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) +
    cyclophosphamide (Alkylating agent)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Breast Cancer Res Treat
    Title:

    Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark

    Published date:
    04/30/2022
    Excerpt:
    We restricted the cohort to women diagnosed with breast cancer after implementation of docetaxel in combination with cyclophosphamide and sometimes epirubicin as guideline chemotherapy in Denmark....Mortality was increased in variant carriers of GSTP1 rs1138272 (HR: 1.30, 95% CI 0.95–1.78) and CYP3A rs10273424 (HR: 1.33, 95% CI 0.98–1.81). SLCO1B1 rs2306283 (encoding OATP1B1) variant carriers had decreased recurrence (HR: 0.82, 95% CI 0.64–1.07) and mortality (HR: 0.77, 95% CI 0.60–0.98)....Docetaxel effectiveness was influenced by SNPs in GSTP1, CYP3A, and SLCO1B1 in premenopausal women with non-distant metastatic breast cancer...
    DOI:
    10.1007/s10549-022-06596-2